Tidal Investments LLC acquired a new stake in Tango Therapeutics, Inc. (NASDAQ: TNGX) in the second

Tango Therapeutics (TNGX) reported earnings 30 days ago. What's next for the stock?

U.S. stocks fell, but Caleres surged 14% on strong results and higher guidance. Opus Genetics, Signe

BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (Tango Therapeuti

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (“Tango Therapeut

Algert Global LLC boosted its holdings in shares of Tango Therapeutics, Inc. (NASDAQ: TNGX) by 86.5%

Bank of America Corp DE trimmed its stake in Tango Therapeutics, Inc. (NASDAQ: TNGX) by 31.6% in the

ADAR1 Capital Management LLC bought a new position in shares of Tango Therapeutics, Inc. (NASDAQ: TN

HC Wainwright & Co. analyst Robert Burns maintains Tango Therapeutics (NASDAQ:TNGX) with a Bu

Vopimetostat's combination with daraxonrasib has produced an unusually strong early pancreatic-cance

Tango Therapeutics stock falls 5% on a wider-than-expected Q2 loss, reflecting higher operating expe

Guggenheim analyst Michael Schmidt maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and rais

Up to $400,000,000Common StockWe have previously entered into a Sales Agreement, or the sales agreem

Tango Therapeutics (NASDAQ:TNGX) reported quarterly losses of $(0.37) per share which missed the ana

BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage

Medical sector earnings are off to a strong start, and four biotech companies are positioned to pote

Shares of Tango Therapeutics, Inc. (NASDAQ: TNGX - Get Free Report) have received an average rating

The average of price targets set by Wall Street analysts indicates a potential upside of 49.5% in Ta

Tango Therapeutics, Inc. (NASDAQ: TNGX - Get Free Report)'s share price shot up 6.1% on Friday. The

Mizuho analyst Joseph Catanzaro maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperform and

Wall Street analysts initiated coverage on various top stocks, including VCYT, UMAC, FISN, LTRX, and

JP Morgan analyst Brian Cheng initiates coverage on Tango Therapeutics (NASDAQ:TNGX) with a Overw

Tango Therapeutics' strong 2026 rally reflects promising clinical progress, but its premium valuatio

TNGX is advancing precision oncology with MTAP-targeted therapies and 2026 data readouts that could

Tango Therapeutics enters a pivotal phase as vopimetostat drives its investment case, with 2026 clin

Canaccord Genuity analyst John Newman maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and r

Jefferies analyst Maury Raycroft upgrades Tango Therapeutics (NASDAQ:TNGX) from Hold to Buy and r

BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage

BOSTON, June 09, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clini

Tango Therapeutics rises 53% after early pancreatic cancer study data show strong response rates for

HC Wainwright & Co. analyst Robert Burns maintains Tango Therapeutics (NASDAQ:TNGX) with a Bu

AAPL, SUNE, TNGX, APLD, CBRS were among the stocks seen trending on Monday, June 8, 2026.

Tango Therapeutics, Inc. ("Tango") (NASDAQ:TNGX), a clinical-stage biotechnology company com

US stocks rose with Nasdaq up 400 points. Dow up 0.32%, Nasdaq up 1.55%, S&P 500 up 0.94%. Tech

U.S. stocks higher, Nasdaq Composite up 1%. Tango Therapeutics (TNGX) shares up 34.1% on positive tr

Tango Therapeutics reports 90% 6-month PFS in pancreatic cancer trial. Read about the vopimetostat c

Initial data from ongoing Phase 1/2 trial in patients with second and third line PDAC treated with v

US stocks down, S&P 500 falls 1%; Dow down 1.08%, NASDAQ down 1.42%. Energy shares up 1.5%; mate

Mizuho analyst Joseph Catanzaro maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperform and

Top analysts changed outlook on top names. See all rating changes on analyst ratings page. Check out

U.S. stock futures lower, Nasdaq down 1%. DeFi Technologies (DEFT) shares fell 5.3% after Q1 results

Piper Sandler analyst Kelsey Goodwin downgrades Tango Therapeutics (NASDAQ:TNGX) from Overweight

Figma Inc (NYSE: FIG) shares rose 10.6% in pre-market trading after beating Q1 revenue and earnings

Jefferies analyst Maury Raycroft downgrades Tango Therapeutics (NASDAQ:TNGX) from Buy to Hold and

Leerink Partners analyst Andrew Berens maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperfo

Wedbush analyst Robert Driscoll maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperform and

Stifel analyst Laura Prendergast maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and raises

Top analysts change outlook on top names: HC Wainwright & Co. cut FEAM price target, Bernstein d